Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in moderate-to-severe COPD with type 2 inflammation
2018-001953-28Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupilumab every 2 weeks with Placebo every 2 weeks (2 arms). Primary endpoint: Annual rate of acute COPD exacerbation (AECOPD). Started Mar 2019; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-001953-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001953-28.